The impact of omega-3 fatty acids, vitamins, minerals, N-acetylcysteine, and ginkgo biloba on the course and treatment of schizophrenia: A review of research and therapeutic perspectives
DOI:
https://doi.org/10.12775/QS.2025.41.59840Keywords
omega-3 fatty acids, vitamins, minerals, N-acetylcysteine, gut-brain axisAbstract
Schizophrenia is a mental disorder with a complex etiology involving both genetic and environmental factors. Despite advancements in antipsychotic treatments, many patients continue to experience chronic symptoms and medication side effects. As a result, there is growing interest in dietary supplements and bioactive substances to complement traditional therapies and improve patient quality of life. Omega-3 fatty acids, vitamins, minerals, N-acetylcysteine, and ginkgo biloba have shown potential in supporting schizophrenia treatment. These substances may help regulate neuroinflammation, neurotransmission disturbances, oxidative stress, and improve cognitive function. This review examines the scientific evidence on their effects and explores the mechanisms behind their potential benefits in schizophrenia management.
References
Nagle JL, Kumar BS, Bennett MJ, Diebold GE, Pope JK, Sorge H, et al. Source size determination in relativistic nucleus-nucleus collisions. Phys Rev Lett [Internet]. 1994 [cited 2025 Mar 20];73(9):1219–22. Available from: https://pubmed.ncbi.nlm.nih.gov/10057655/
Bozzatello P, Novelli R, Montemagni C, Rocca P, Bellino S. Nutraceuticals in Psychiatric Disorders: A Systematic Review. Int J Mol Sci [Internet]. 2024 May 1 [cited 2025 Mar 20];25(9). Available from: https://pubmed.ncbi.nlm.nih.gov/38732043/
Dyall SC. Long-chain omega-3 fatty acids and the brain: a review of the independent and shared effects of EPA, DPA and DHA. Front Aging Neurosci [Internet]. 2015 [cited 2025 Mar 20];7(APR). Available from: https://pubmed.ncbi.nlm.nih.gov/25954194/
Goh KK, Chen CYA, Chen CH, Lu ML. Effects of omega-3 polyunsaturated fatty acids supplements on psychopathology and metabolic parameters in schizophrenia: A meta-analysis of randomized controlled trials. J Psychopharmacol [Internet]. 2021 Mar 1 [cited 2025 Mar 20];35(3):221–35. Available from: https://pubmed.ncbi.nlm.nih.gov/33586517/
Song C, Shieh CH, Wu YS, Kalueff A, Gaikwad S, Su KP. The role of omega-3 polyunsaturated fatty acids eicosapentaenoic and docosahexaenoic acids in the treatment of major depression and Alzheimer’s disease: Acting separately or synergistically? Prog Lipid Res [Internet]. 2016 Apr 1 [cited 2025 Mar 20];62:41–54. Available from: https://pubmed.ncbi.nlm.nih.gov/26763196/
Postila PA, Róg T. A Perspective: Active Role of Lipids in Neurotransmitter Dynamics. Mol Neurobiol [Internet]. 2020 Feb 1 [cited 2025 Mar 20];57(2):910–25. Available from: https://pubmed.ncbi.nlm.nih.gov/31595461/
Yao JK, Sistilli CG, Van Kammen DP. Membrane polyunsaturated fatty acids and CSF cytokines in patients with schizophrenia. Prostaglandins Leukot Essent Fatty Acids [Internet]. 2003 [cited 2025 Mar 20];69(6):429–36. Available from: https://pubmed.ncbi.nlm.nih.gov/14623497/
Xia J, Yang L, Huang C, Deng S, Yang Z, Zhang Y, et al. Omega-3 Polyunsaturated Fatty Acid Eicosapentaenoic Acid or Docosahexaenoic Acid Improved Ageing-Associated Cognitive Decline by Regulating Glial Polarization. Mar Drugs [Internet]. 2023 Jul 1 [cited 2025 Mar 20];21(7). Available from: https://pubmed.ncbi.nlm.nih.gov/37504929/
Calder PC. Omega-3 fatty acids and inflammatory processes. Nutrients [Internet]. 2010 [cited 2025 Mar 20];2(3):355–74. Available from: https://pubmed.ncbi.nlm.nih.gov/22254027/
Xu F, Fan W, Wang W, Tang W, Yang F, Zhang Y, et al. Effects of omega-3 fatty acids on metabolic syndrome in patients with schizophrenia: a 12-week randomized placebo-controlled trial. Psychopharmacology (Berl) [Internet]. 2019 Apr 1 [cited 2025 Mar 20];236(4):1273–9. Available from: https://pubmed.ncbi.nlm.nih.gov/30519766/
Tang W, Wang Y, Xu F, Fan W, Zhang Y, Fan K, et al. Omega-3 fatty acids ameliorate cognitive dysfunction in schizophrenia patients with metabolic syndrome. Brain Behav Immun [Internet]. 2020 Aug 1 [cited 2025 Mar 20];88:529–34. Available from: https://pubmed.ncbi.nlm.nih.gov/32304881/
Kuda O, Rossmeisl M, Kopecky J. Omega-3 fatty acids and adipose tissue biology. Mol Aspects Med [Internet]. 2018 Dec 1 [cited 2025 Mar 20];64:147–60. Available from: https://pubmed.ncbi.nlm.nih.gov/29329795/
Ghosh SS, Wang J, Yannie PJ, Ghosh S. Intestinal Barrier Dysfunction, LPS Translocation, and Disease Development. J Endocr Soc [Internet]. 2020 Feb 1 [cited 2025 Mar 20];4(2). Available from: https://pubmed.ncbi.nlm.nih.gov/32099951/
Bentsen H, Osnes K, Refsum H, Solberg DK, Bøhmer T. A randomized placebo-controlled trial of an omega-3 fatty acid and vitamins E+C in schizophrenia. Transl Psychiatry [Internet]. 2013 Dec 17 [cited 2025 Mar 20];3(12). Available from: https://pubmed.ncbi.nlm.nih.gov/24346133/
Bathina S, Das UN. Brain-derived neurotrophic factor and its clinical implications. Arch Med Sci [Internet]. 2015 Dec 1 [cited 2025 Mar 20];11(6):1164–78. Available from: https://pubmed.ncbi.nlm.nih.gov/26788077/
Pawełczyk T, Grancow M, Kotlicka-Antczak M, Trafalska E, Gȩbski P, Szemraj J, et al. Omega-3 fatty acids in first-episode schizophrenia - a randomized controlled study of efficacy and relapse prevention (OFFER): rationale, design, and methods. BMC Psychiatry [Internet]. 2015 Dec 12 [cited 2025 Mar 20];15(1). Available from: https://pubmed.ncbi.nlm.nih.gov/25934131/
Robinson DG, Gallego JA, John M, Hanna LA, Zhang JP, Birnbaum ML, et al. A potential role for adjunctive omega-3 polyunsaturated fatty acids for depression and anxiety symptoms in recent onset psychosis: Results from a 16 week randomized placebo-controlled trial for participants concurrently treated with risperidone. Schizophr Res [Internet]. 2019 Feb 1 [cited 2025 Mar 20];204:295–303. Available from: https://pubmed.ncbi.nlm.nih.gov/30241990/
Bošković M, Vovk T, Koprivšek J, Plesničar BK, Grabnar I. Vitamin E and essential polyunsaturated fatty acids supplementation in schizophrenia patients treated with haloperidol. Nutr Neurosci [Internet]. 2016 Apr 20 [cited 2025 Mar 20];19(4):156–61. Available from: https://pubmed.ncbi.nlm.nih.gov/25056532/
Sakuma K, Matsunaga S, Nomura I, Okuya M, Kishi T, Iwata N. Folic acid/methylfolate for the treatment of psychopathology in schizophrenia: a systematic review and meta-analysis. Psychopharmacology (Berl) [Internet]. 2018 Aug 1 [cited 2025 Mar 20];235(8):2303–14. Available from: https://pubmed.ncbi.nlm.nih.gov/29785555/
Tang YL, Wang SW, Lin SM. Both inorganic and organic selenium supplements can decrease brain monoamine oxidase B enzyme activity in adult rats. Br J Nutr [Internet]. 2008 [cited 2025 Mar 20];100(3):660–5. Available from: https://pubmed.ncbi.nlm.nih.gov/18304392/
Genchi G, Lauria G, Catalano A, Sinicropi MS, Carocci A. Biological Activity of Selenium and Its Impact on Human Health. Int J Mol Sci [Internet]. 2023 Feb 1 [cited 2025 Mar 20];24(3). Available from: https://pubmed.ncbi.nlm.nih.gov/36768955/
Baj J, Bargieł J, Cabaj J, Skierkowski B, Hunek G, Portincasa P, et al. Trace Elements Levels in Major Depressive Disorder-Evaluation of Potential Threats and Possible Therapeutic Approaches. Int J Mol Sci [Internet]. 2023 Oct 1 [cited 2025 Mar 20];24(20). Available from: https://pubmed.ncbi.nlm.nih.gov/37894749/
Yuan X, Fu Z, Ji P, Guo L, Al-Ghamdy AO, Alkandiri A, et al. Selenium Nanoparticles Pre-Treatment Reverse Behavioral, Oxidative Damage, Neuronal Loss and Neurochemical Alterations in Pentylenetetrazole-Induced Epileptic Seizures in Mice. Int J Nanomedicine [Internet]. 2020 [cited 2025 Mar 20];15:6339–53. Available from: https://pubmed.ncbi.nlm.nih.gov/32922005/
Roffman JL, Lamberti JS, Achtyes E, Macklin EA, Galendez GC, Raeke LH, et al. Randomized multicenter investigation of folate plus vitamin B12 supplementation in schizophrenia. JAMA Psychiatry [Internet]. 2013 May 1 [cited 2025 Mar 20];70(5):481–9. Available from: https://pubmed.ncbi.nlm.nih.gov/23467813/
Zhilyaeva T V., Piatoikina AS, Bavrina AP, Kostina O V., Zhukova ES, Shcherbatyuk TG, et al. Homocysteine in Schizophrenia: Independent Pathogenetic Factor with Prooxidant Activity or Integral Marker of Other Biochemical Disturbances? Schizophr Res Treatment [Internet]. 2021 [cited 2025 Mar 20];2021. Available from: https://pubmed.ncbi.nlm.nih.gov/34707909/
Reilly R, McNulty H, Pentieva K, Strain JJ, Ward M. MTHFR 677TT genotype and disease risk: is there a modulating role for B-vitamins? Proc Nutr Soc [Internet]. 2014 Feb [cited 2025 Mar 20];73(1):47–56. Available from: https://pubmed.ncbi.nlm.nih.gov/24131523/
Hill M, Shannahan K, Jasinski S, Macklin EA, Raeke L, Roffman JL, et al. Folate supplementation in schizophrenia: a possible role for MTHFR genotype. Schizophr Res [Internet]. 2011 Apr [cited 2025 Mar 20];127(1–3):41–5. Available from: https://pubmed.ncbi.nlm.nih.gov/21334854/
Cui X, McGrath JJ, Burne THJ, Eyles DW. Vitamin D and schizophrenia: 20 years on. Mol Psychiatry [Internet]. 2021 Jul 1 [cited 2025 Mar 20];26(7):2708–20. Available from: https://pubmed.ncbi.nlm.nih.gov/33500553/
Gáll Z, Székely O. Role of Vitamin D in Cognitive Dysfunction: New Molecular Concepts and Discrepancies between Animal and Human Findings. Nutrients [Internet]. 2021 Nov 1 [cited 2025 Mar 20];13(11). Available from: https://pubmed.ncbi.nlm.nih.gov/34835929/
Kalejahi P, Kheirouri S, Noorazar SG. A randomized controlled trial of Vitamin D supplementation in Iranian patients with schizophrenia: Effects on serum levels of glycogen synthase kinase-3β and symptom severity. Int J Psychiatry Med [Internet]. 2023 Nov 1 [cited 2025 Mar 20];58(6):559–75. Available from: https://pubmed.ncbi.nlm.nih.gov/37545122/
Valipour G, Saneei P, Esmaillzadeh A. Serum vitamin D levels in relation to schizophrenia: a systematic review and meta-analysis of observational studies. J Clin Endocrinol Metab [Internet]. 2014 Oct 1 [cited 2025 Mar 20];99(10):3863–72. Available from: https://pubmed.ncbi.nlm.nih.gov/25050991/
McGrath J, Saari K, Hakko H, Jokelainen J, Jones P, Järvelin MR, et al. Vitamin D supplementation during the first year of life and risk of schizophrenia: A Finnish birth cohort study. Schizophr Res [Internet]. 2004 Apr 1 [cited 2025 Mar 20];67(2–3):237–45. Available from: https://pubmed.ncbi.nlm.nih.gov/14984883/
Li Z, Liu Y, Li X, Ju W, Wu G, Yang X, et al. Association of Elements with Schizophrenia and Intervention of Selenium Supplements. Biol Trace Elem Res [Internet]. 2018 May 1 [cited 2025 Mar 20];183(1):16–21. Available from: https://pubmed.ncbi.nlm.nih.gov/28812245/
Jamilian H, Ghaderi A. The Effects of Probiotic and Selenium Co-supplementation on Clinical and Metabolic Scales in Chronic Schizophrenia: a Randomized, Double-blind, Placebo-Controlled Trial. Biol Trace Elem Res [Internet]. 2021 Dec 1 [cited 2025 Mar 20];199(12):4430–8. Available from: https://pubmed.ncbi.nlm.nih.gov/33409919/
Nechifor M, Vaideanu C, Palamaru I, Borza C, Mindreci I. The influence of some antipsychotics on erythrocyte magnesium and plasma magnesium, calcium, copper and zinc in patients with paranoid schizophrenia. J Am Coll Nutr [Internet]. 2004 Oct 1 [cited 2025 Mar 20];23(5):549S-551S. Available from: https://pubmed.ncbi.nlm.nih.gov/15466963/
Smaga I, Frankowska M, Filip M. N-acetylcysteine as a new prominent approach for treating psychiatric disorders. Br J Pharmacol [Internet]. 2021 Jul 1 [cited 2025 Mar 20];178(13):2569–94. Available from: https://pubmed.ncbi.nlm.nih.gov/33760228/
DeFeudis F, Drieu K. Ginkgo biloba extract (EGb 761) and CNS functions: basic studies and clinical applications. Curr Drug Targets [Internet]. 2000 Mar 25 [cited 2025 Mar 20];1(1):25–58. Available from: https://pubmed.ncbi.nlm.nih.gov/11475535/
Oberpichler H, Sauer D, Roßberg C, Mennel HD, Krieglstein J. PAF antagonist ginkgolide B reduces postischemic neuronal damage in rat brain hippocampus. J Cereb Blood Flow Metab [Internet]. 1990 [cited 2025 Mar 20];10(1):133–5. Available from: https://pubmed.ncbi.nlm.nih.gov/2298830/
DeFeudis F, Drieu K. Ginkgo biloba extract (EGb 761) and CNS functions: basic studies and clinical applications. Curr Drug Targets [Internet]. 2000 Mar 25 [cited 2025 Mar 20];1(1):25–58. Available from: https://pubmed.ncbi.nlm.nih.gov/11475535/
Ginkgo biloba - PubMed [Internet]. [cited 2025 Mar 20]. Available from: https://pubmed.ncbi.nlm.nih.gov/13678141/
Watanabe CMH, Wolffram S, Ader P, Rimbach G, Packer L, Maguire JJ, et al. The in vivo neuromodulatory effects of the herbal medicine ginkgo biloba. Proc Natl Acad Sci U S A [Internet]. 2001 Jun 5 [cited 2025 Mar 20];98(12):6577–80. Available from: https://pubmed.ncbi.nlm.nih.gov/11381109/
Yang YS, Maddock RJ, Zhang H, Lee J, Hellemann G, Marder SR, et al. N-Acetylcysteine effects on glutathione and glutamate in schizophrenia: A preliminary MRS study. Psychiatry Res Neuroimaging [Internet]. 2022 Sep 1 [cited 2025 Mar 20];325. Available from: https://pubmed.ncbi.nlm.nih.gov/35839558/
Pyatoykina AS, Zhilyaeva T V., Semennov I V., Mishanov GA, Blagonravova AS, Mazo GE. [The double-blind randomized placebo-controlled trial of N-acetylcysteine use in schizophrenia: preliminary results]. Zh Nevrol Psikhiatr Im S S Korsakova [Internet]. 2020 [cited 2025 Mar 20];120(9):66–71. Available from: https://pubmed.ncbi.nlm.nih.gov/33081449/
Conus P, Seidman LJ, Fournier M, Xin L, Cleusix M, Baumann PS, et al. N-acetylcysteine in a Double-Blind Randomized Placebo-Controlled Trial: Toward Biomarker-Guided Treatment in Early Psychosis. Schizophr Bull [Internet]. 2018 Mar 1 [cited 2025 Mar 20];44(2):317–27. Available from: https://pubmed.ncbi.nlm.nih.gov/29462456/
Tardiolo G, Bramanti P, Mazzon E. Overview on the Effects of N-Acetylcysteine in Neurodegenerative Diseases. Molecules [Internet]. 2018 Dec 13 [cited 2025 Mar 20];23(12). Available from: https://pubmed.ncbi.nlm.nih.gov/30551603/
Mullier E, Roine T, Griffa A, Xin L, Baumann PS, Klauser P, et al. N-Acetyl-Cysteine Supplementation Improves Functional Connectivity Within the Cingulate Cortex in Early Psychosis: A Pilot Study. Int J Neuropsychopharmacol [Internet]. 2019 Aug 1 [cited 2025 Mar 20];22(8):478–87. Available from: https://pubmed.ncbi.nlm.nih.gov/31283822/
Neill E, Rossell SL, Yolland C, Meyer D, Galletly C, Harris A, et al. N-Acetylcysteine (NAC) in Schizophrenia Resistant to Clozapine: A Double-Blind, Randomized, Placebo-Controlled Trial Targeting Negative Symptoms. Schizophr Bull [Internet]. 2022 Nov 1 [cited 2025 Mar 20];48(6):1263–72. Available from: https://pubmed.ncbi.nlm.nih.gov/35857752/
Singh V, Singh SP, Chan K. Review and meta-analysis of usage of ginkgo as an adjunct therapy in chronic schizophrenia. Int J Neuropsychopharmacol [Internet]. 2010 Mar [cited 2025 Mar 20];13(2):257–71. Available from: https://pubmed.ncbi.nlm.nih.gov/19775502/
Zhang XY, Zhou DF, Zhang PY, Wu GY, Su JM, Cao LY. A double-blind, placebo-controlled trial of extract of Ginkgo biloba added to haloperidol in treatment-resistant patients with schizophrenia. J Clin Psychiatry [Internet]. 2001 [cited 2025 Mar 20];62(11):878–83. Available from: https://pubmed.ncbi.nlm.nih.gov/11775047/
Doruk A, Uzun Ö, Özşahin A. A placebo-controlled study of extract of ginkgo biloba added to clozapine in patients with treatment-resistant schizophrenia. Int Clin Psychopharmacol [Internet]. 2008 Jul [cited 2025 Mar 20];23(4):223–7. Available from: https://pubmed.ncbi.nlm.nih.gov/18545061/
Montes P, Ruiz-Sanchez E, Rojas C, Rojas P. Ginkgo biloba Extract 761: A Review of Basic Studies and Potential Clinical Use in Psychiatric Disorders. CNS Neurol Disord Drug Targets [Internet]. 2015 Feb 9 [cited 2025 Mar 20];14(1):132–49. Available from: https://pubmed.ncbi.nlm.nih.gov/25642989/
Zhang WF, Tan YL, Zhang XY, Chan RCK, Wu HR, Zhou DF. Extract of Ginkgo biloba treatment for tardive dyskinesia in schizophrenia: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry [Internet]. 2011 May [cited 2025 Mar 20];72(5):615–21. Available from: https://pubmed.ncbi.nlm.nih.gov/20868638/
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Patrycja Niczyporuk, Izabela Zajkowska, Aleksandra Giba, Kamila Iłendo, Wiktor Królikiewicz, Rafał Marecki, Aleksandra Kicman
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 44
Number of citations: 0
